Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy
Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.
For the past 30 years, KRAS was believed to be an undruggable target, which has made the emergence of KRAS G12C inhibitors all the more exciting, according to Levy.
The compound that has gained the most notoriety because of its unprecedented activity is AMG 510, said Levy. AMG 510 is a first-in-class investigational agent that selectively and irreversibly targets the KRAS G12C protein.
In September 2019, the FDA granted a fast track designation to the investigational KRAS inhibitor for the treatment of patients with KRAS G12C–mutated NSCLC who have received prior treatment. Watch the video or read the transcript here.